Vanguard Group Inc. boosted its holdings in shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) by 6.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 282,483 shares of the company’s stock after acquiring an additional 17,455 shares during the quarter. Vanguard Group Inc. owned 1.21% of Aquinox Pharmaceuticals worth $3,974,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Northern Trust Corp lifted its holdings in shares of Aquinox Pharmaceuticals by 3.3% in the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after buying an additional 2,691 shares during the period. Sphera Funds Management LTD. purchased a new stake in shares of Aquinox Pharmaceuticals in the 2nd quarter worth $874,000. Archon Partners LLC lifted its holdings in shares of Aquinox Pharmaceuticals by 44.0% in the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after buying an additional 5,500 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Aquinox Pharmaceuticals by 16.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after buying an additional 3,299 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in shares of Aquinox Pharmaceuticals by 4.7% in the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after buying an additional 939 shares during the period. Institutional investors own 93.22% of the company’s stock.
Shares of Aquinox Pharmaceuticals Inc (NASDAQ AQXP) opened at $10.80 on Friday. Aquinox Pharmaceuticals Inc has a 12 month low of $10.20 and a 12 month high of $19.97.
COPYRIGHT VIOLATION NOTICE: “Aquinox Pharmaceuticals Inc (AQXP) Position Boosted by Vanguard Group Inc.” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/03/aquinox-pharmaceuticals-inc-aqxp-position-boosted-by-vanguard-group-inc.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Want to see what other hedge funds are holding AQXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).
What are top analysts saying about Aquinox Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aquinox Pharmaceuticals Inc and related companies.